Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals took a tumble today and lost -€3.500 (-3.550%).
The stock is an absolute favorite of our community with 39 Buy predictions and no Sell predictions.
With a target price of 109 € there is a slightly positive potential of 14.74% for Rhythm Pharmaceuticals compared to the current price of 95.0 €.
Our community identified positive and negative aspects for Rhythm Pharmaceuticals stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Rhythm Pharmaceuticals stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Rhythm Pharmaceuticals in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rhythm Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | -3.550% | 11.932% | 22.360% | 89.350% | 88.517% | 264.815% | 303.689% |
| Ardelyx Inc. | 0.230% | 2.840% | 4.881% | 6.187% | 6.465% | 184.469% | -6.409% |
| Krystal Biotech | 0.720% | 3.678% | 18.962% | 33.718% | 37.057% | 193.803% | - |
| Evolus Inc | 1.750% | -1.724% | -7.317% | -46.729% | -45.714% | -13.636% | 73.622% |
Comments
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Ratings data for RYTM provided by MarketBeat
News
Rhythm Stock: Obesity Drug Spurs Analyst Optimism
Rhythm Pharmaceuticals has captured Wall Street's attention following impressive Phase 2 results for its experimental obesity medication, Bivamelagon. The biotech company's shares surged 10% after
